GREAT POST!
I'm going to some analysis of RXP v ASZ tomorrow.
RXP Ridiculously undervalued. High ROE and low payout ratio with ongoing growth in both top line and NPAT while delivering solid margins.
On your point re asking investors for capital for acquisitions, I'm fine with this providing we don't see ROE diluted.
I've got plenty of RXP and won't be selling this side of $1.25.
Market soaring, RXP dead, page-35
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
